Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 3c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.62), $0.03 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $0 versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
• Syndax publishes SAVE trial data on Revuforj combination therapy in AML